For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Celldex Therapeutics Inc’s stock clocked out at $21.44, down -3.12% from its previous closing price of $22.13. In other words, the price has decreased by -$3.12 from its previous closing price. On the day, 0.99 million shares were traded. CLDX stock price reached its highest trading level at $21.92 during the session, while it also had its lowest trading level at $20.71.
Ratios:
To gain a deeper understanding of CLDX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 21.67 and its Current Ratio is at 21.67. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Canaccord Genuity on April 28, 2025, initiated with a Buy rating and assigned the stock a target price of $64.
On March 20, 2025, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $46.
On February 13, 2025, UBS started tracking the stock assigning a Buy rating and target price of $44.UBS initiated its Buy rating on February 13, 2025, with a $44 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 11 ’24 when Marucci Anthony S bought 11,500 shares for $26.82 per share. The transaction valued at 308,430 led to the insider holds 40,284 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLDX now has a Market Capitalization of 1423491712 and an Enterprise Value of 753629504. For the stock, the TTM Price-to-Sale (P/S) ratio is 188.29 while its Price-to-Book (P/B) ratio in mrq is 2.02. Its current Enterprise Value per Revenue stands at 99.7 whereas that against EBITDA is -3.523.
Stock Price History:
The Beta on a monthly basis for CLDX is 1.20, which has changed by -0.34454298 over the last 52 weeks, in comparison to a change of 0.19283521 over the same period for the S&P500. Over the past 52 weeks, CLDX has reached a high of $47.00, while it has fallen to a 52-week low of $14.40. The 50-Day Moving Average of the stock is 0.13%, while the 200-Day Moving Average is calculated to be -4.76%.
Shares Statistics:
It appears that CLDX traded 1.03M shares on average per day over the past three months and 900920 shares per day over the past ten days. A total of 66.38M shares are outstanding, with a floating share count of 64.51M. Insiders hold about 2.84% of the company’s shares, while institutions hold 110.93% stake in the company. Shares short for CLDX as of 1752537600 were 8469593 with a Short Ratio of 8.22, compared to 1749772800 on 7828519. Therefore, it implies a Short% of Shares Outstanding of 8469593 and a Short% of Float of 15.07.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Celldex Therapeutics Inc (CLDX) is currently under the scrutiny of 11.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.88, with high estimates of -$0.77 and low estimates of -$0.96.
Analysts are recommending an EPS of between -$3.08 and -$3.67 for the fiscal current year, implying an average EPS of -$3.4. EPS for the following year is -$4.11, with 9.0 analysts recommending between -$3.2 and -$4.81.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for CLDX’s current fiscal year. The highest revenue estimate was $9.7M, while the lowest revenue estimate was $695k, resulting in an average revenue estimate of $3.81M. In the same quarter a year ago, actual revenue was $7.02M
